Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10794	Companies
233239	Keywords
161823	Articles
124413	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 07/02/2024 at 13:30, 2 years 1 month ago

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness

Moderna Inc. MRNA Technology BARDA Pandemic Influenza Vaccine Global Public Health
BRIEF

published on 06/28/2024 at 13:05, 2 years 1 month ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 2 years 1 month ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 2 years 1 month ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 2 years 1 month ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 2 years 1 month ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 2 years 1 month ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 2 years 1 month ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
PRESS RELEASE

published on 06/07/2024 at 16:30, 2 years 1 month ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 2 years 1 month ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Accesswire

Published on 08/01/2026 at 01:20, 2 days 7 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 7 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 8 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 8 hours ago

BioNxt Solutions Announces Option Grants
Published on 07/31/2026 at 23:20, 2 days 9 hours ago

Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 08:15, 19 minutes ago

CPI PROPERTY GROUP – Summer Update
Published on 08/03/2026 at 08:00, 34 minutes ago

Transaction in Own Shares
Published on 08/03/2026 at 08:00, 34 minutes ago

Invitation to the earnings call on 11 August 2026: presentation of unaudited 6M 2026 results
Published on 08/03/2026 at 07:30, 1 hour 4 minutes ago

2CRSi SA: Independent investigation into the allegations made in the Grizzly Research report: 2CRSi sets out the scope and timetable
Published on 08/03/2026 at 07:30, 1 hour 4 minutes ago

q.beyond acquires majority stake in SAP healthcare specialist GITG

Les Echos

Published on 08/03/2026 at 08:29, 5 minutes ago

Launch of a €225 million tranche of its share buyback programme
Published on 08/03/2026 at 07:00, 1 hour 34 minutes ago

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Published on 07/31/2026 at 21:00, 2 days 11 hours ago

Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 13 hours ago

Share retention commitments (Dutreil Agreement)
Published on 07/31/2026 at 19:14, 2 days 13 hours ago

2026 First-Half financial report

View all LES ECHOS COMFI WIRE